Vittoria Biotherapeutics Reveals Interim Phase 1 Data for VIPER-101
Vittoria Biotherapeutics, Inc., an innovative clinical-stage immunotherapy company, has announced an exciting development in its first-in-human Phase 1 study of VIPER-101. This groundbreaking treatment involves CD5-modulated autologous CAR-T therapy tailored for patients facing relapsed or refractory T-cell lymphoma (TCL). The interim clinical data will be shared at the prestigious American Society of Hematology annual meeting scheduled for December 6-9.
Challenges in T-Cell Lymphoma Treatment
According to the company’s CEO, Nicholas Siciliano, Ph.D., T-cell lymphoma presents significant challenges due to the limited advancement in therapeutic options over the years. SICILIANO stated, "Our interim clinical data presents compelling evidence of the translatability and potential therapeutic benefits of our Senza5 platform technology." He expressed great optimism about the ability of their CD5-targeted, dual-population CAR-T candidate to dramatically change the treatment landscape for individuals living with this condition.
Details of the Presentation at ASH
The details regarding the presentation are as follows:
Title: First in human Phase 1 dose finding study (VIPER 101) of dual population autologous CD5 deleted anti-CD5 CAR T (Senza5 CART5) cells in Relapsed/Refractory T cell lymphomas
Date: December 7
Time: 6:00 PM – 8:00 PM ET
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II
Location: OCCC - West Halls B3-B4
Publication Number: 4174
Following the presentation, an electronic version of the poster will be accessible on Vittoria's website.
Understanding VIPER-101
VIPER-101 stands out as a gene-edited, autologous, dual-population cell therapy. It targets CD5, a marker found on cancer cells impacting over 85% of patients with T-cell lymphoma. The therapy highlights the revolutionary capabilities of the Senza5 platform, which enhances T-cell functionality by eliminating CD5-related immunosuppression through gene editing. Preclinical research has shown VIPER-101 to outperform traditional CD5-targeted CAR T therapies in efficacy.
Senza5 Platform: Innovation in Cell Therapy
The Senza5™ platform represents a major technological advancement within the field of cell therapies. By leveraging genetic engineering techniques and a proprietary five-day manufacturing process, this platform enhances the stemness, durability, and effectiveness of T cell therapies. Specifically, it mitigates the immunosuppressive effects of CD5 signaling to augment anti-tumor activity. This accelerated manufacturing process also significantly promotes in vivo expansion and longevity of the therapeutic response.
A Commitment to Transforming Cell Therapies
Vittoria Biotherapeutics is dedicated to developing novel CAR T cell therapies that challenge the boundaries of current treatment methodologies. Their approach utilizes exclusive technology licensed from the University of Pennsylvania to harness the full cytotoxic potential of engineered T cells. The efficacy of Senza5’s platform is applicable in treating solid tumors and autoimmune diseases, paving a brighter future in immunotherapy.
Investor and Media Contacts
Investor Contact:
Vittoria Biotherapeutics, Inc.
Nicholas A. Siciliano, Ph.D.
Chief Executive Officer
+1 215-600-1380
Media Contact:
LifeSci Communications
Jason Braco, Ph.D.
+1 646-876-4932
Frequently Asked Questions
What is VIPER-101?
VIPER-101 is a gene-edited autologous CAR-T therapy being investigated for treating relapsed or refractory T-cell lymphoma.
When is the data presentation scheduled?
The presentation will take place on December 7, from 6:00 PM to 8:00 PM ET.
What does Senza5™ bring to cell therapy?
Senza5™ improves T cell therapies by enhancing their efficacy and durability through advanced engineering techniques.
Who is Vittoria Biotherapeutics targeting with their therapies?
Vittoria's therapies focus on patients with T-cell lymphoma and other related conditions.
How can investors get in touch with Vittoria?
Investors can contact Nicholas A. Siciliano at +1 215-600-1380 for inquiries.